The Lancet Rheumatology in conversation with

In today’s episode Professor Eric Morand discusses the results of Cohort A and Cohort B of the WILLOW trial which investigated the efficacy and safety of enpatoran, a novel, oral small molecule inhibitor of Toll-like receptors 7 and 8 (TLR 7/8) in patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE). The interferon pathway has been implicated in both CLE and SLE...

In this month’s podcast, we explore Associate Professor Kragstrup’s recent proof-of-concept study which reports glucagon-like peptide-1 (GLP-1) concentrations and dipeptidyl peptidase-4 (DPP-4) activity in paired plasma and synovial fluid from patients with rheumatoid arthritis and spondyloarthritis and discuss whether there may be potential for intra-articular GLP-1 receptor agonist injections in...

In this episode, Professor Dirk Foell from University Hospital Münster unpacks the findings from a recent Europe-wide survey examining trends in paediatric rheumatology care. Despite significant scientific advances, delivering consistent, high-quality care for children with rheumatic and musculoskeletal diseases remains a challenge. Drawing on Professor Foell's recent Viewpoint, we discuss variati...

As part of The Lancet Rheumatology’s special issue on public and patient involvement in rheumatology, in this month’s episode, Aisling talks to Professor Jon Lampa about his recent publication on the patient-reported outcomes from the NORD-STAR trial. The 2023 NORD-STAR trial was the first randomised trial to compare three different biological DMARDs, all in combination with methotrexate with acti...

In this month’s episode we discuss childhood-onset Sjögren’s disease-a rare and under-researched rheumatic condition.  Lack of robust clinical and immunological characterisation of this condition alongside assessment of its impact on quality of life has significantly hampered progress in the delivery of high-quality research and evidence-based recommendations for care.  There are currently no stud...

This months episode covers Hemophagocytic lymphohistiocytosis, or HLH, a rare, life-threatening disorder characterised by dysregulated immune activity resulting in systemic inflammation, tissue damage and multiorgan failure which affects both children and adults. The annual prevalence of HLH in England is around 2 per million people in the adult population, with an overall 1-year survival rate of...

During this episode, Dr John Isaacs and Dr Josh Bennett from Newcastle University and the NIHR Newcastle Biomedical Research Centre, discuss sarcopenia - an age-related loss of muscle mass and strength. Sarcopenia is relatively common in rheumatoid arthritis, with a prevalence ranging from 4·5% to 44% of people with rheumatoid arthritis, depending on the definition of sarcopenia used. Rheumatoid s...

This month's episode covers Sjögren’s disease—an autoimmune condition that primarily affects areas of the body that produce fluids, such as tears and saliva. The cause of the disease isn’t understood. Currently there are no licensed drugs to treat the disease, but phase 2 clinical trials have reported encouraging results, and phase 3 trials are underway. Dr Samuel Bitoun, from the University of Pa...

In today's episode, Sophie discusses psoriatic arthritis with Dr Ryan Hum from The University of Manchester. Psoriatic arthritis affects between 0.1% and 1% of the general population globally, and appears to be more prevalent in certain regions. It affects men and women equally and typically appears between the ages of 30 and 55 years. Psoriatic arthritis tends to be more common in people with pso...

In this episode, we’re tackling a condition that affects over 374 million people worldwide—knee osteoarthritis (OA). As the most common site of OA, knee OA is a leading cause of disability and accounts for more than 12 million disability-adjusted life years globally. With prevalence rising steadily due to aging populations and increasing obesity rates, the burden of knee OA is projected to climb e...

In this episode, we'll be discussing an issue that affects millions of people globally - low back pain. We will find out why the burden of low back pain is so high, why current management is so ineffective, what we can do from a research and care perspective to improve outcomes for patients, and whether prevention is the way forward.  We’ll also discuss a couple of papers that have been recently p...

In this episode Professor Vibeke Strand discusses polymyalgia rheumatica (or PMR), a common inflammatory rheumatic disease that significantly impairs patients’ quality of life, causing fatigue, pain, and physical disability, especially in relapsing cases that often require long-term glucocorticoid treatment. However, these treatments come with considerable side effects, and many patients do not re...

This is a joint podcast between The Lancet Rheumatology and The Lancet Regional Health - Western Pacific with Prof Xue Li. Biologics have become a mainstay of treatment in Rheumatology in Western populations, but in many parts of Asia, especially lower-and-middle-income countries, there remains substantial inequity in access due to differences in availability and affordability. In this episode, we...

In this podcast, Professor Savic talks about his recent publication that looks at treatment outcomes in patients with VEXAS syndrome, as well as what clinicians should look out for in patients (red flags), and future priorities for research. VEXAS syndrome (short for Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome) was first described in 2020. It’s a rare, and often-life threaten...

This is the third and final episode of our mini-series on cell-based therapies in rheumatology, with Professor Fabian Müller and Dr Melanie Hagen from the Erlangen University, Germany. We discuss their recently published a study on a newly discovered toxicity of CD-19 targeting CAR T-cell therapy in patients with autoimmune disease, as well as the recent successes of CAR T-cell therapy, ideal pati...

This is the second episode of a mini series on cell-based therapies in rheumatology, with Prof. Dominique Farge discussing the use of allogeneic umbilical cord-derived mesenchymal stromal cells (MSCs) as treatment for systemic lupus erythematosus (SLE).  We cover the limited options currently available for people with severe or refractory SLE, the complexities in using MSCs, Prof. Farge's recent s...

The first episode of a mini series on cell-based therapies in rheumatology, with Prof Rebecca Marsh and Grant Schulert discussing the use of allogeneic haematopoietic stem-cell transplantation for children with refractory systemic juvenile idiopathic arthritis and associated lung disease. Read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00275-3/fulltext?dgc...

Dr Bryant England discusses the use of TNF-inhibitor versus non-TNF inhibitor biological or targeted synthetic DMARDs for treatment of rheumatoid arthritis-associated ILD, and the effects on survival and respiratory hospitalisation outcomes. Read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00265-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanrhe Continu...

Dr Brooke Conley and Associate Professor Ivan Lin discuss their recent study on integrating evidence from lived experience of Aboriginal people and clinical practice guidelines to develop arthritis educational resources. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https:...

Dr Mark Russell and Sherry Yang discuss the factors influencing initiation of biologics in underserved populations with rheumatoid arthritis in the UK, how historical redlining and present-day racialised economic segregation affects health-care utilisation of adults with rheumatic diseases in the USA, and health inequities seen in rheumatology more broadly. Read the full article: https://www.thela...

Dr Quirine Dumoulin discusses the efficacy of a 1-year course of methotrexate on the development of rheumatoid arthritis in ACPA-negative people with clinically suspect arthralgia and predicted increased risk of rheumatoid arthritis. Read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00196-6?dgcid=buzzsprout_icw_podcast_generic_lanrhe Continue this conversati...

Dr Sebastian Sattui discusses the effects of age and frailty on the risks of end-stage renal disease, death, and severe infection in older adults with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00193-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanrhe Continue this conversation on so...

To celebrate 5 years of The Lancet Rheumatology, international advisory board members Oliver Distler, Laura Coates, and David Liew discuss recent progress made, challenges to overcome, and future directions in rheumatology. Read the associated Editorial: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00245-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanrhe Continue this con...

Dr Karen Schreiber, Professor Ian Giles, and Professor Angela Tincani discuss the Series on Pregnancy and Rheumatic Diseases, including the use of DMARDs during pregnancy, study design and conduct, and outcomes for children born to mothers with rheumatic diseases. Read the Series: https://thelancet.com/series/pregnancy-rheumatic-diseases?dgcid=buzzsprout_icw_podcast_generic_lanrhe Continue this co...

Dr Maria Tektonidou discusses the results of a cross-sectional analysis of international data on cardiovascular risk factors in systemic lupus erythematosus. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancet...